RAIN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 saus. 2024 @ 23:00):

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States...

Stats
Dzisiejszy wolumen	3.70M
Średni wolumen	238 293
Kapitalizacja rynkowa	44.01M
EPS	$0 ( 2024-03-14 )
Następna data zysków	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.585
ATR14	$0.0380 (3.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-26	Tang Kevin C	Sell	3 850 513	Common Stock
2024-01-25	Bvf Partners L P/il	Sell	185 388	Common Stock, $0.001 par value
2024-01-25	Bvf Partners L P/il	Sell	341 547	Non-Voting Common Stock, $0.001 par value
2024-01-26	Bvf Partners L P/il	Sell	35 000	Stock Option (Right to Buy)
2024-01-26	Bvf Partners L P/il	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-57.40
Last 98 transactions
Buy: 6 387 020 \| Sell: 11 238 556

Wolumen Korelacja

Długi: 0.27 (neutral)

Krótki: -0.45 (neutral)

Signal:(53.89) Neutral

Rain Therapeutics Inc. Korelacja

10 Najbardziej pozytywne korelacje
KVSC	0.96
PPD	0.957
QQD	0.949
QQC	0.947
FTIV	0.944
ESTA	0.943
DXJS	0.941
GEEX	0.94
ADTH	0.938
EGLE	0.937

10 Najbardziej negatywne korelacje
OM	-0.969
TSLA	-0.964
WW	-0.96
NVTS	-0.956
GEVO	-0.956
OPI	-0.955
FWRD	-0.954
CLNE	-0.953
VUZI	-0.952
AEHR	-0.945

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rain Therapeutics Inc. Korelacja - Waluta/Towar

0.59
( weak )

0.82
( strong )

0.00
( neutral )

0.44
( neutral )

-0.50
( neutral )

-0.62
( weak negative )

Rain Therapeutics Inc. Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.71

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.71

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.942

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.980

Financial Reports:

No articles found.

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.